Yanming Z Zu

20110287096, Nov 24, 2011

May 18, 2011

13/110591

Sudhir GORUKANTI - Tuxedo Park NY, US
Yanming Zu - Highland Mills NY, US
Phanidhara Kotamraj - Westwood NJ, US
Karunakar Neelam - New Milford NJ, US
Salah U. Ahmed - New City NY, US

ABON PHARMACEUTICALS, LLC - Northvale NJ

A61K 9/62
A61K 31/506
A61K 9/58
A61K 9/56
A61K 9/26
A61K 9/54

424461, 424469, 424458, 424462, 424459, 51425219

Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.

20090196935, Aug 6, 2009

Feb 2, 2009

12/364241

Salah U. Ahmed - New City NY, US
Pruthvipathy R. Katikaneni - Boonton NJ, US
Yanming Zu - Highland Mills NY, US

A61K 9/14
A61K 31/519
A61P 25/00

424494, 424490, 5142621, 424497

The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke.

20230000824, Jan 5, 2023

Jul 6, 2022

17/811026

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Tahseen A. CHOWDHURY - Township of Washington NJ, US
Mohammed Irfan SYED - Dumont NJ, US

A61K 31/4025
A61K 47/38
A61K 9/00
A61K 47/32
A61K 47/36
A61K 47/26

The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

20210379090, Dec 9, 2021

Jun 7, 2021

17/340862

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Hetalben PRAJAPATI - Dumont NJ, US
Mohammed I. SYED - Dumont NJ, US
Tahseen A. CHOWDHURY - Township Of Washington NJ, US

A61K 31/675
A61K 9/48
A61K 9/00

The present disclosure provides a remdesivir oral delivery system bypassing the first pass hepatic metabolism. More specifically, the disclosure relates to an oral dosage form of remdesivir comprising a lipid based vehicle in an enteric capsule designed to be delivered at intestine to be absorbed by lymphatic pathway, therefore minimizing the first pass hepatic metabolism and improving the oral bioavailability. In some embodiments, the disclosure provides an oral dosage form comprising: (a) remdesivir; (b) a lipid-based vehicle comprising a lipophilic vehicle, an amphiphilic vehicle, a none-aqueous hydrophilic vehicle, or combinations thereof; and (c) an enteric capsule; wherein the remdesivir is dissolved or dispersed in the lipid-based vehicle; and, wherein the remdesivir and the lipid-based vehicle are in the enteric capsule. It also relates to methods of designing and making this dosage form, and methods of usage of this dosage form in the early treatment and prophylaxis of coronavirus infections, e.g., COVID-19.

20190388392, Dec 26, 2019

Jun 7, 2019

16/435071

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Tahseen A. CHOWDHURY - Township of Washington NJ, US
Mohammed Irfan SYED - Dumont NJ, US

A61K 31/4025
A61K 47/38
A61K 9/00
A61K 47/26
A61K 47/36
A61K 47/32

The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

20170196802, Jul 13, 2017

Aug 12, 2016

15/235763

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Jason LePREE - Demarest NJ, US
Hetalben PRAJAPATI - New Milford NJ, US
Tahseen A. CHOWDHURY - Washington-Township NJ, US

Abon Pharmaceuticals, LLC - Northvale NJ

A61K 9/00
A61K 31/496
A61K 47/26
A61K 47/22
A61K 47/10
A61K 31/5415
A61K 31/675
A61K 47/14
A61K 47/44

The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C-Cfatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a Dparticle size of about 0.5 μm to about 25 μm in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25 C.

20170196855, Jul 13, 2017

Oct 24, 2016

15/332592

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Jason LePREE - Demarest NJ, US
Hetalben PRAJAPATI - New Milford NJ, US
Tahseen A. CHOWDHURY - Washington-Township NJ, US

Abon Pharmaceuticals, LLC - Northvale NJ

A61K 31/496
A61K 47/26
A61K 47/44
A61K 47/34
A61K 47/22
A61K 47/10
A61K 31/675
A61K 9/00
A61K 47/20
A61K 31/495
A61K 9/08
A61K 31/5415

The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 μm to about 25 μm in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25 C.